EPS taps CluePoints for trial management solution

By Jenni Spinner contact

- Last updated on GMT

(Image: Getty/bestbrk)
(Image: Getty/bestbrk)

Related tags: Clinical trial, CluePoints, Risk management

The Japanese pharma development firm will harness risk-based quality management solutions to help sponsors improve trial quality and safety.

CluePoints, which specializes in providing risk-based study execution (RBx) and data quality oversite software for trial clients, has agreed to provide risk-based quality management (RBQM solutions to EPS sponsors. The aim of the implementation is to help drive early risk detection, improve quality and increase patient safety, cost-effectively and resource-efficiently.

Best practices

According to CluePoints, clinical research and pharmaceutical professionals are increasingly interested in using RBQM to boost efficiently and quality. Furthermore, the technology is designed to enable sponsors and CROS to comply with regulatory mandates, such as European Medicines Agency (EMA) rules around good clinical practice.

Patrick Hughes, chief commercial officer for CluePoints, told Outsourcing-Pharma that RBQM enables study managers to improve quality of studies from start to finish.

Risk management underpins the overall quality of the trial by identifying, controlling and communicating​,” he said. “RBQM encompasses all elements of the study, from planning right through to execution​.”

Hughes added the EMA’s ICH E6 (R2) spells out what the optimal RBQM system should include:

  • Critical process and data identification
  • Risk identification
  • Risk evaluation
  • Risk control
  • Risk communication
  • Risk review
  • Risk reporting

Critical components

Hughes explained the CluePoints solution was designed to tackle each element within the guidance, empowering sponsors and CROs to address each key component.

The CluePoints Risk Assessment solution allows users to quickly and easily collaborate to identify critical process and data and evaluate both the risks themselves and the controls required to mitigate the risks throughout the study,​” he said. “This allows full documentation and audit trails and is designed to be revisited at regular intervals throughout the study​.”

Additionally, Hughes explained, users can uncover inherent risks using different elements within the portfolio. This is made possible through CluePoints proprietary statistical algorithms.

The CluePoints approach incorporates Central Statistical Monitoring (CSM), an unsupervised, independent and objective analysis of clinical and operational data. Organizations in Europe and North American have been adopting the approach to identify risks early on, and EPS plans to adopt CSM with its clients (largely in Japan) and elsewhere.

Tools designed into the central monitoring platform include risk assessment, key risk indicators, data surveillance, patient profiles and more. Clients are able to choose modules that fit their particular needs to implement RBQM in their operations.

Related news

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars